The ACME Laboratories Ltd. (DSE:ACMELAB)

Market Cap	17.01B
Revenue (ttm)	34.75B
Net Income (ttm)	2.40B
Shares Out	211.60M
EPS (ttm)	11.36
PE Ratio	7.08
Forward PE	n/a
Dividend	3.50 (4.35%)
Ex-Dividend Date	Nov 21, 2024

Volume	538,221
Average Volume	300,943
Open	78.90
Previous Close	78.30
Day's Range	78.70 - 80.80
52-Week Range	67.60 - 94.50
Beta	0.08
RSI	71.54
Earnings Date	Oct 22, 2025

About United States Steel

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacture, market, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and stero...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 9,301
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In 2024, The ACME Laboratories's revenue was 31.93 billion, an increase of 18.49% compared to the previous year's 26.95 billion. Earnings were 2.46 billion, an increase of 6.62%.